The Regulatory Consultant You Hired Doesn't Actually Know Your Technology

You found someone with twenty years of regulatory experience. They've walked products through 510(k)s, PMAs, EPA submissions, USDA approvals, you name it. Their LinkedIn is a cathedral of credentials. You wrote them a check and exhaled for the first time in months.

Photo by Markus Winkler on Pexels.

That exhale was premature.

Here's what usually happens: the consultant knows process cold. They know timelines, submission formats, reviewer tendencies, and which agency office will eat your lunch if you schedule a pre-submission meeting without enough data. What they don't know, and won't admit, is your actual technology. And in deep tech, that gap is where startups bleed out.

Regulatory strategy for novel technologies isn't a form-filling exercise. It's a translation problem. You have to take something genuinely new, a bioelectronic sensor, a photocatalytic water treatment system, a cell-based therapeutic that doesn't fit existing product codes, and convince a regulator that they have the tools to evaluate it. That requires someone who understands both sides of the conversation. Most consultants only speak one language fluently.

So what goes wrong in practice?

They default to the nearest precedent, even when it doesn't fit.

Consultants survive on pattern matching. They've seen hundreds of submissions; yours gets slotted into the closest historical category. Sometimes that works. When it doesn't, you end up pursuing a regulatory pathway that was designed for a different kind of product, and you don't find out until the agency sends back a deficiency letter eighteen months later asking questions your consultant never anticipated because they never truly understood what your device actually does.

A founder I spoke with spent fourteen months pursuing a De Novo classification for a continuous monitoring device before a new technical advisor pointed out that the intended use language in the submission was quietly describing a diagnostic claim the team never intended to make. The consultant had borrowed that language from a previous client's successful submission. It was comfortable. It was wrong.

They optimize for approval probability, not commercial reality.

Getting cleared is not the same as getting cleared for something useful. Consultants, especially those paid by the hour with no equity stake, are incentivized to get you across the finish line. That means narrowing your intended use to whatever the agency is most likely to accept. Narrow indications, conservative labeling, stripped-down claims.

You end up with a cleared product that your sales team can barely sell because the label doesn't say what the customer needs it to say. Regulatory strategy and commercial strategy have to be built together, from the beginning. That only happens when your regulatory person actually understands why someone would buy your technology in the first place.

The pre-submission meeting becomes theater.

Pre-submission meetings with FDA, or equivalent early-dialogue mechanisms with other agencies, are genuinely valuable. They're also one of the most wasted opportunities in early-stage deep tech. When your consultant doesn't understand your underlying science, the questions they prepare are generic. The agency's feedback stays generic in return. You leave with polite non-answers when you could have walked out with a clear signal on your biggest technical uncertainty.

Agencies respond to specificity. The more precisely you can describe your technology, your test methods, and your specific open questions, the more useful the response. That requires someone who did the reading, not just on regulatory precedents, but on your actual bench work.

graph TD
    A[Novel Technology] --> B{Does consultant understand the science?}
    B -->|No| C[Nearest precedent pathway]
    B -->|Yes| D[Purpose-built regulatory strategy]
    C --> E[Deficiency letters / wrong pathway]
    D --> F[Pre-sub meeting with real answers]
    E --> G((Delay + Burn))
    F --> H((Faster, commercially useful clearance))

So what do you actually do?

First, treat regulatory strategy as a technical problem, not an administrative one. Whoever leads it, consultant, fractional VP, or eventual in-house hire, needs to be able to read your data and argue about it. If they can't push back on your study design, they can't defend it to a reviewer either.

Second, don't outsource the pre-submission meeting preparation entirely. You should be writing the first draft of your questions. The consultant refines; you provide the substance. That division of labor produces much sharper submissions.

Third, verify their precedents. When a consultant says "we'll follow the same pathway as Product X," pull the 510(k) summary or the approval package yourself. Read the intended use statement. Read the special controls. If it doesn't actually match your technology, say so out loud before you commit twelve months to following it.

Experience with the process is worth paying for. Understanding of your technology is non-negotiable. The mistake is assuming you can get one without the other.